Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
| Agency: | |
|---|---|
| Level of Government: | Federal |
| Category: |
|
| Opps ID: | NBD00159071155626953 |
| Posted Date: | Dec 18, 2023 |
| Due Date: | |
| Source: | https://sam.gov/opp/0d678800b6... |
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
- Contract Opportunity Type: Solicitation (Updated)
- All Dates/Times are: (UTC-06:00) CENTRAL STANDARD TIME, CHICAGO, USA
- Updated Published Date: Dec 18, 2023 02:22 pm CST
- Original Published Date:
- Requirements Strategy:
- Inactive Policy: Manual
- Updated Inactive Date: Jun 21, 2024
- Original Inactive Date:
- Authority:
- Fair Opportunity / Limited Sources Justification Authority:
-
Initiative:
- None
- Original Set Aside:
- Product Service Code:
-
NAICS Code:
-
Place of Performance:
San Antonio , TX 78230USA
The Department of Defense (DoD) is required by law (10 U.S.C. ยง 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: February 2024: The following drug classes/subclass will be reviewed
a. GROWTH STIMULATING AGENTS: NA
Genotropin
Humatrope
Ngenla
Norditropin Flexpro
Nutropin AQ Nuspin
Omnitrope
Saizen
Saizen-Saizenprep
Serostim
Skytrofa
Sogroya
Zomacton
b. PULMONARY-1 AGENTS: INHALED CORTICOSTEROIDS
Alvesco
Armonair Digihaler
Arnuity Ellipta
Asmanex
Asmanex HFA
Flovent Diskus
Flovent HFA
Fluticasone Propionate HFA
Pulmicort Flexhaler
Qvar Redihaler
c. MULTIPLE SCLEROSIS AGENTS: SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS
Gilenya
Mayzent
Ponvory
Tascenso ODT
Zeposia
The RFQ, including UF BPA and UF ADP appendices are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-24-Q-9101.
Pre-quote teleconference is on November 8, 2023, details are stated in Part 2.5. Pre-quote teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC (stated in Part 2.3), no later than the date stated in Part 2.4.
- Tracy Banks
- tracy.e.banks2.civ@health.mil
- Julia Trang
- julia.n.trang.civ@health.mil
TRY FOR FREE
Not a USAOPPS Member Yet?
Get unlimited access to thousands of active local, state and federal government bids and awards in All 50 States.